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depends on NMDA receptor-gated and
L-type Ca2+ channels upstream of p38 MAPK
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and Marcus Kaul1,2*
Abstract
Background: The chemokine receptor CXCR4 (CD184) and its natural ligand CXCL12 contribute to many physiological
processes, including decisions about cell death and survival in the central nervous system. In addition, CXCR4 is a
co-receptor for human immunodeficiency virus (HIV)-1 and mediates the neurotoxicity of the viral envelope protein
gp120. However, we previously observed that CXCL12 also causes toxicity in cerebrocortical neurons but the cellular
mechanism remained incompletely defined.
Methods: Primary neuronal-glial cerebrocortical cell cultures from rat were exposed to a neurotoxicity-inducing
CXCL12 concentration for different times and the activity of the stress-associated mitogen-activated protein kinase
p38 (p38 MAPK) was assessed using an in vitro kinase assay. Neurotoxicity of CXCL12 and cellular localization of p38
MAPK was analyzed by immunofluorescence microscopy. Pharmacological inhibition of NMDA-type glutamate
receptor-gated ion channels (NMDAR) of L-type Ca2+ channels was employed during 12- and 24-h exposure to
neurotoxic amounts of CXCL12 to study the effects on active p38 MAPK and neuronal survival by Western blotting and
microscopy, respectively. Neurotoxicity of CXCL12 was also assessed during pharmacological inhibition of p38 MAPK.
Results: Here, we show that a neurotoxic amount of CXCL12 triggers a significant increase of endogenous p38 MAPK
activity in cerebrocortical cells. Immunofluorescence and Western blotting experiments with mixed neuronal-glial and
neuron-depleted glial cerebrocortical cells revealed that the majority of active/phosphorylated p38 MAPK was located
in neurons. Blockade of NMDAR-gated ion channels or L-type Ca2+ channels both abrogated an increase of active p38
MAPK and toxicity of CXCL12 in cerebrocortical neurons. Inhibition of L-type Ca2+ channels with nimodipine kept the
active kinase at levels not significantly different from baseline while blocking NMDAR with MK-801 strongly reduced
phosphorylated p38 MAPK below baseline. Finally, we confirmed that directly blocking p38 MAPK also abrogated
neurotoxicity of CXCL12.
Conclusions: Our findings link CXCL12-induced neuronal death to the regulation of NMDAR-gated ion channels and
L-type Ca2+ channels upstream of p38 MAPK activation.
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Background
The chemokine receptor CXCR4 (CD184) and its physio-
logical ligand stromal cell-derived factor (SDF)-1/CXCL12
are both widely and constitutively expressed throughout
the mammalian organism and play important biological
roles in development and tissue homeostasis [1–4].
As such, the CXCR4/CXCL12 receptor-ligand system is
involved in many physiological processes beyond chemo-
taxis, including embryogenesis, vascularization, brain de-
velopment, neurogenesis, hematopoiesis, inflammation,
tissue repair, and cancer [2, 4–7]. While cell migration
along the chemokine gradient contributes in most of these
processes, the functions of CXCR4 and CXCL12 in the
central nervous system (CNS) also include the regulation
of axonal outgrowth and patterning, synaptic function,
and plasticity as well as decisions about cell death and
survival (reviewed in [4–6, 8, 9]). One of the best recog-
nized pathological function of CXCR4 is its role as a
co-receptor during infection with human immunodefi-
ciency virus (HIV)-1 and the ability of CXCL12 to inter-
fere in the infection process, at least in vitro [10, 11].
Furthermore, we and others have shown that CXCR4
can mediate the induction of neuronal injury and apop-
tosis by HIV-1 envelope protein gp120 [12–16], a neuro-
toxic process that downstream of chemokine receptor
engagement also involves excessive excitatory activation of
the N-methyl-D-aspartate type of glutamate receptors
(NMDAR) [17]. HIV-1 infection can result in proteolytic
cleavage of CXCL12, and the truncated chemokine exerts
neurotoxicity through a CXCR3-mediated pathway [18].
However, investigating whether CXCL12 can prevent a
CXCR4-using HIV-1 gp120 from inducing neuronal apop-
tosis, we observed that full-length CXCL12 itself is toxic
to terminally differentiated cerebrocortical neurons via a
pathway that depended on CXCR4 and implicated p38
mitogen-activated protein kinase (p38 MAPK) [12, 13].
We also found that exposure to CXCL12 triggered a
transient increase of intracellular Ca2+ in cerebrocortical
neurons [13]. Others have linked neurotoxic CXCR4
activation to astrocytic release of glutamate which in turn
was stimulated via a pathway involving tumor necrosis
factor (TNF)α, prostaglandins, and microglial activation
[19]. The release of astrocytic glutamate suggested that
neuronal glutamate receptors and excitotoxicity may
contribute to CXCR4-mediated neurotoxicity. Neuronal
excitotoxicity is associated with excessive influx of extra-
cellular Ca2+ resulting in intracellular Ca2+ overload,
downstream activation of p38 MAPK and p53, release of
cytochrome c and other molecules from mitochondria,
such as apoptosis-inducing factor, activation of caspases,
free radical formation, lipid peroxidation, chromatin
condensation, and eventually apoptosis [20, 21]. Conside-
ring the importance of Ca2+ in excitotoxicity, it was there-
fore not surprising that inhibitors of Ca2+ ion channels,
including NMDA-type glutamate receptor-gated ion
channels (NMDAR), were found to prevent toxicity of
HIV gp120 [19, 22, 23]. Here, we show that blockade of
L-type Ca2+ channels and NMDAR both prevent CXCR4-
mediated toxicity of CXCL12 in cerebrocortical neurons.
We also demonstrate that a neurotoxic concentration
of CXCL12 increases the amount of active, phosphor-
ylated p38 MAPK, which is primarily located in neu-
rons. Moreover, we find that inhibition of L-type Ca2+
channels and NMDAR limits or diminishes the activa-
tion of the stress kinase in neurons. Finally, we con-
firm that directly blocking p38 MAPK also abrogates
neurotoxicity of CXCL12. Hence, both types of Ca2+
channels appeared to control CXCL12-induced neur-
onal death upstream of p38 MAPK.
Methods
Primary rat cerebrocortical cell cultures
Mixed neuronal-glial cerebrocortical cell cultures, con-
taining neurons, astrocytes, and microglia, were prepared
from E16 Sprague-Dawley rat embryos (Harlan Sprague
Dawley Inc., San Diego, CA) as previously described
[12, 13, 24, 25]. Briefly, cerebrocortical cells from embryos
were plated on poly-L-lysine-coated glass coverslips in
35-mm plastic dishes or 96-well plates for imaging
(Falcon, BD Biosciences) and generally used for experi-
ments after 17 days in vitro when the cultures contained
~30 % neurons, ~70 % astrocytes, and ~0.1 to 1 % micro-
glia, and neurons were fully differentiated and sensitive to
NMDA-induced excitotoxicity [12, 13]. To obtain glial
cells, neurons were depleted by treating cerebrocortical
cultures with 300-μM NMDA for 20 min 2 days prior to
the experiment and preparation of cell lysate [24, 25].
All experimental procedures and protocols involving
animals were in accordance with the NIH guidelines
and approved by the Institutional Animal Care and Use
Committee of the Sanford Burnham Prebys Medical
Discovery Institute.
Reagents
Recombinant CXCL12 (SDF-1β) was purchased from
R&D Systems (Minneapolis, MN). Lyophilized CXCL12
preparations were reconstituted at micromolar (μM)
concentrations in phosphate-buffered saline (PBS) con-
taining 0.1 % BSA as carrier to 100 times the final con-
centration. Aliquots of reconstituted chemokine were
stored at −80 °C until use [12, 13].
The non-competitive NMDAR antagonist MK-801
(dizocilpine maleate; (5R,10S)-(+)-5-methyl-10,11-dihydro-
5H-dibenzo[a,d]-cyclohepten-5-10-imine, maleate) [26], the
L-type Ca2+ channel blocker nimodipine (1,4-dihydro-2,6-
dimethyl-4-(3′-nitrophenyl)-3,5-pyridinedicarboxylic acid
2-methoxyethyl-1-methylethyl ester) [27, 28], and the spe-
cific p38 MAPK inhibitor SB203580 [29] were purchased
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from EMD/Calbiochem (San Diego, CA) and reconstituted
at 1000 times the final concentration in tissue culture-
quality dimethyl sulfoxide (DMSO) (ATCC, Manassas, VA).
Aliquots of reconstituted reagents were stored at −20 °C
until use.
Experimental treatment of cerebrocortical cell cultures
For experiments, cultures were transferred into pre-
warmed Earle’s Balanced Salt Solution (EBSS) containing
1.8 mM Ca2+ and 5 μM glycine without additional Mg2+
or serum-free culture media. The cells were then incu-
bated for 24 h in toxicity assays or for indicated time
periods in kinase assay and Western blotting experiments
in the presence or absence of MK-801 or nimodipine
or SB203580 or CXCL12, or combinations thereof while
the controls received vehicles only (BSA at 0.001 % and
DMSO at 0.1 % final concentrations) as described before
[12, 13, 25]. Following the incubation, the cultures were
either fixed for immunofluorescence staining and assess-
ment of neurotoxicity or lysed for protein kinase and
Western blotting assays.
Immunofluorescence staining and microscopy
The cerebrocortical cell cultures were fixed in 4 %
paraformaldehyde (PFA) in PBS for 25 min at 4 °C
and permeabilized with 0.2 TX-100. Neurons were
immunolabeled with an antibody for neuron-specific
microtubule-associated protein-2 (MAP-2; clone HM2,
Sigma) and nuclei with the DNA dyes Hoechst 33342
or propidium iodide [12, 13, 24, 25]. For the inves-
tigation of cellular phospho p38 MAPK, the fixation
of the cells in 4 % PFA was followed by ice-cold methanol
for 10 min before permeabilization and immunostaining
with anti-active p38 MAPK antibody (Ab) (Promega, WI)
in combination with anti-MAP-2 [24] and labeling of
nuclear DNA with the dye DRAQ5 (Thermo Fisher
Scientific). Fluorescence microscopy was performed using a
computer-controlled Axiovert 200-M microscope equipped
with filters for DAPI, FITC, CY3, and CY5 (Zeiss) and a
cooled CCD camera (Hamamatsu). Images were recorded
and analyzed using the SlideBook software package (Intelli-
gent Imaging Innovations, Denver, CO) as described earlier
[13, 24, 30].
For the purpose of comparison, all samples of a given
experiment were imaged under identical conditions, and
the respective fluorescence channels were set to identical
dynamic ranges in all images of the various experimental
conditions. For better visualization, the fluorescence
signal of DRAQ5 was shown in blue pseudocolor.
Assessment of neurotoxicity
Neurotoxicity was assessed by fluorescence microscopy
as previously described using a combination of immuno-
staining for neuron-specific MAP-2 and identification
of pyknotic apoptotic nuclei after staining all nuclei
with the DNA dyes Hoechst 33342 or propidium iodide
[12, 13, 24, 25]. Neuronal survival was calculated using
neuronal cell counts after subtracting MAP-2+ cells
that displayed pyknotic or fragmented nuclei indicating
apoptosis. The percentage of neurons was compared
between the various experimental conditions and ve-
hicle controls, which were defined as 100 % with regard
to neuronal survival.
Cell lysates, kinase assays, and immunoblotting
For the preparation of cell lysates for immunoblotting and
protein kinase assays, cells were washed with ice-cold PBS
and harvested in Triton X-100 Cell Lysis Buffer (20 mM
Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM Na2EDTA,
1 mM EGTA, 1 % Triton X-100, 2.5 mM sodium pyro-
phosphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4,
1 μg/ml leupeptin; Cell Signaling Technologies; Beverly,
MA) supplemented with 5 mM NaF (serine/threonine
protein phosphatase inhibitor) and Complete Protease In-
hibitor Cocktail (Roche; Indianapolis, IN) on ice for
10 min. The lysed samples were transferred into micro-
centrifuge tubes, sonicated four times for 5 s, and then
cleared by centrifugation (13,200 x g, 10 min) at 4 °C. Lys-
ate total protein concentrations were determined using
the bicinchoninic acid (BCA) protein assay kit (Pierce/
Thermo Fisher Scientific; Rockford, IL).
For immunoblotting, equal amounts of protein (usually
30 μg per lane) were separated by SDS-PAGE under redu-
cing conditions and electroblotted onto polyvinyl difluo-
ride (PVDF) membrane. After blocking remaining binding
sites with BSA, the membranes were probed sequentially
with anti-phospho p38 MAPK Ab (Promega, WI), total
p38 MAPK Ab (Cell Signaling Technologies), anti-phos-
pho c-Jun N-terminal kinase (JNK) Ab, total JNK Ab
(both Cell Signaling Technologies), anti-NeuN Ab
(Chemicon), anti-synaptophysin Ab (Dako), anti Actin Ab
(Millipore), and anti-α-tubulin Ab (Sigma) as described
earlier [24, 25].
Activity of p38 MAPK and JNK was estimated using
commercially available in vitro immunocomplex protein
kinase assays following the supplier’s instructions (Cell
Signaling Technologies). The assays were standardized
for equal volumes of lysate, beads for precipitation, indi-
cator substrate (ATF-2 or c-Jun), elution, SDS-PAGE,
and Western blotting procedure. Following immunopre-
cipitation, the kinase activities of p38 and JNK were
detected using recombinant ATF-2 or c-Jun, respectively,
as indicator substrates. Phosphorylated assay substrates
(ATF-1 and c-Jun) were detected using an immunoblot-
based non-radioactive system employing phosphorylation
site-specific antibodies for visualization, and densitometry
was used for quantification as recently described [24].
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Statistical analysis
Comparisons of more than two experimental groups were
subjected to analysis of variance (ANOVA) followed by
Fisher’s PLSD post hoc test. Analysis of two experimental
conditions used student’s t test. Statistical analysis was
performed with the StatView software package (version
5.0.1, SAS Institute, Cary, NC).
Results
CXCL12 compromises neuronal survival in a
concentration-dependent fashion
First, the mixed neuronal-glial cerebrocortical cells were
incubated for 24 h with CXCL12 at three different con-
centrations, 2, 20, and 50 nM. BSA (0.001 % final concen-
tration) served as vehicle control in the absence of
CXCL12. Following the incubation, the cell cultures were
fixed, permeabilized, and fluorescence labeled for neuron-
specific microtubule-associated protein-2 (MAP-2) and
nuclear DNA as described in the “Methods” section. Com-
paring cell numbers and the percentages of neurons be-
tween the experimental conditions showed that CXCL12
reduced neuronal survival in a concentration-dependent
fashion, Fig. 1, thus expanding our earlier observations
using apoptosis and survival assays [12, 13].
Blockade of Ca2+ channels prevents neurotoxicity of
CXCL12
We previously showed that a neurotoxic concentration
of CXCL12 triggers a transient increase of intracellular
Ca2+ in cerebrocortical neurons [13]. Therefore, we next
incubated cerebrocortical cells for 24 h with 20 nM of
CXCL12 in the presence or absence of the NMDAR
antagonist MK-801 (1 and 10 μM) or the L-type Ca2+
channel inhibitor nimodipine (10 nM). DMSO (0.1 %)
served as vehicle control in the absence of MK-801 and
nimodipine and BSA (0.001 %) as protein carrier control
in the absence of CXCL12. The intermediate neurotoxic
concentration of CXCL12 was chosen since it was initially
unknown if the Ca2+ channel blockers would promote or
prevent neurotoxicity of the CXCR4 ligand. The concen-
trations of MK-801 and nimodipine were derived from
earlier reports of their protective effect against neuroto-
xicity of HIV-1 envelope protein gp120 [17]. Subsequent
assessment of neurotoxicity showed that MK-801 at
10 μM and nimodipine at 10 nM completely abrogated
neurotoxicity of CXCL12, Fig. 2. Interestingly and in
contrast to its combination with CXCL12, MK-801 alone
exerted a slight, yet significant, toxic effect at 10 μM
concentration. However, MK-801 at 1 μM concentration
was not toxic but also failed to protect neurons from
CXCL12 toxicity. Nimodipine alone lacked any detectable
influence on neuronal survival.
Fig. 1 CXCL12 compromises neuronal survival in a concentration-
dependent fashion. Mixed neuronal-glial cerebrocortical cell cultures
were incubated for 24 h with CXCL12 at concentrations of 2, 20, and
50 nM. BSA (0.001 % final concentration) served as vehicle control in the
absence of CXCL12. Assessment of neuronal survival was performed as
described in the text using cell counting after fluorescence staining for
neuronal MAP-2 and nuclear DNA. Values are mean ± SEM; n≥ 3 with
duplicate or triplicate samples per condition; **P≤ 0.01; ***P≤ 0.001 by
ANOVA followed by Fisher’s PLSD post hoc test
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CXCL12 activates p38 MAPK in cerebrocortical neurons
Using immunofluorescence microscopy, we previously
found that in cerebrocortical cell cultures, active, phos-
phorylated p38 MAPK is primarily located to neurons
and microglia, both of which, respectively, make up
about 30 % and less than 1 % of the total cerebrocortical
cell population [24]. Here, we compared cell lysates of
complete neuro-glial (N+G) and neuron-depleted, glial
cerebrocortical cultures (G) by Western blotting. Immu-
nodetection of NeuN and synaptophysin was used to
detect the presence and absence of neurons in N+G
and G samples, respectively. We found that with this
approach, phosphorylated p38 MAPK was strongly
detectable in complete neuron-containing cerebrocortical
cells, but not neuron-depleted glial cultures, which com-
prise about 98.6 % astrocytes and about 1.4 % microglia,
Fig. 3a. This finding was consistent with the earlier obser-
vation that activation of p38 MAPK is predominantly
detected in cerebrocortical neurons, which contribute the
majority of kinase activity detected in immunocomplex
kinase assays [24]. However, inactive, non-phosphorylated
kinase is also found in glial cells. Surprisingly, the active,
phosphorylated form of a second stress-related protein
kinase, JNK, was predominantly detected in cerebrocorti-
cal cultures containing neurons and even the inactive,
non-phosphorylated form of the kinase was only weakly
detectable in glial cells.
Although neurons have high baseline activity of p38
MAPK compared to astrocytes and our studies had
implicated the protein kinase in CXCL12 neurotoxicity,
the activation kinetic of p38 MAPK in CXCL12-exposed
cerebrocortical cells was previously unknown. Therefore,
we first performed immunocomplex kinase assays using
cell lysates harvested 10 and 30 min and 12 and 24 h
after addition of CXCL12 or vehicle. For comparison,
we also analyzed the activity of a second stress-related
protein kinase, JNK. Figure 3b shows that, compared with
the controls, p38 MAPK activity was consistently and
significantly increased at 10 and 30 min and most pro-
nounced 12 h exposure to CXCL12, while at 24 h, the
level of kinase activity in CXCL12-exposed samples was
on average below, yet not significantly distinct from the
controls. The activity of JNK in the presence of CXCL12
did not significantly differ from control at any of the
assessed time points, Fig. 3b.
In additional experiments, we exposed mixed neuronal-
glial cerebrocortical cell cultures for 12 h to 20 nM
CXCL12 or vehicle control and subsequently fixed, perme-
abilized, and labeled the cells for phosphorylated p38
MAPK and neuronal MAP-2 as described in the “Methods”
section. Immunofluorescence microscopy showed that
phosphorylated p38 MAPK was primarily detected in -
neurons and with increased fluorescence intensity after
exposure to CXCL12, Fig. 4.
Inhibition of Ca2+ channels counteracts CXCL12-induced
activation of p38 MAPK
Since activation of p38 MAPK in neurons is influenced
by intracellular Ca2+ levels [21] and we had previously
shown that CXCL12 induces a transient increase of
Fig. 2 Ca2+ channel blockers MK-801 and nimodipine abrogate
neurotoxicity of CXCL12 in cerebrocortical cell cultures. Incubation
with CXCL12 and Ca2+ channel blockers and assessment of neuronal
survival was performed as described in the text using staining for
neurons (MAP-2) and nuclear DNA. Representative images are shown
for six experimental conditions (MK-801 at 10 μM). Scale bar, 20 μm.
Values in the graph are mean ± SEM; n≥ 3 with duplicate or triplicate
samples per condition; *P≤ 0.05, ***P≤ 0.001 by ANOVA followed by
Fisher’s PLSD post hoc test
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intracellular Ca2+ levels in neurons [13], we hypothe-
sized that the Ca2+ channel blockers might limit neur-
onal death-inducing activation of the kinase by CXCL12.
Therefore, we next employed Western blotting to esti-
mate active p38 MAPK in cell lysates of cerebrocortical
cells incubated for 12 and 24 h with a neurotoxic amount
of CXCL12 (20 nM) in the presence or absence of
MK-801 (10 μM) or nimodipine (10 nM). As before,
DMSO (0.1 %) served as vehicle control in the absence of
MK-801 and nimodipine, and BSA (0.001 %) as protein
carrier control in the absence of CXCL12, Fig. 5. Detection
of active/phosphorylated p38 MAPK by immunoblotting
Fig. 3 Neurotoxic CXCL12 transiently activates p38 MAPK and JNK in rat cerebrocortical cultures. a Complete neuro-glial cell cultures and neuron-depleted
cerebrocortical cell cultures were analyzed by Western blotting for the presence of active p38 MAPK and JNK. To obtain glial cells, neurons were depleted
by treating cerebrocortical cultures with 300 μM NMDA for 20 min 2 days prior to the preparation of cell lysates. Equal amounts of cellular protein
(30 μg) were separated by SDS-PAGE and analyzed by immunoblotting for the indicated proteins. A representative Western blot from one of the three
independent neuron depletion experiments is shown. b Cerebrocortical cultures were incubated with recombinant CXCL12 (20 nM) for the indicated time
periods, prior to cell lysis on ice. Equal amounts of cellular protein (100 μg) were used for the performance of immunocomplex kinase assays as described
in the “Methods” section. The Western blots show representative samples of phosphorylated indicator substrates observed with samples of the 12 and 24
h time points. Kinase activity in CXCL12-exposed samples and vehicle-treated controls was measured for each time point. Vehicle controls were defined as
the 100 % baseline value. Note the difference in the dimension of time on the split X-axis. Each time point represents four to seven assessments in
duplicate or triplicate in independent experiments. *P≤ 0.05 compared to control by student’s t test. ‘pp38’/‘p-p38’ and ‘p-JNK’ indicate phosphorylated
p38 MAPK and JNK, respectively
Fig. 4 Phosphorylated p38 MAPK in cerebrocortical cell cultures localizes to neurons with and without CXCL12 exposure. Cerebrocortical cell cultures
from rats were incubated with CXCL12 (20 nM). After 12 h of treatment, cells were fixed, permeabilized, and stained for MAP-2 (red), as a neuronal
marker, activated-phospho p38 MAPK (green), and nuclear DNA (DRAQ5; shown in blue pseudocolor for better visualization). Samples were analyzed
using immunofluorescence microscopy as described in the “Methods” section. The overlap of red and green signals appears yellow in the merged
images. Scale bars, 20 μm
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confirmed, besides the presence of active p38 MAPK under
baseline conditions, the activity pattern upon CXCL12
exposure detected with the kinase assay at 12 and 24 h.
Moreover, the immunoblotting experiments revealed
that MK-801, but not nimodipine, significantly reduced
the activation of p38 MAPK at 12 and 24 h. However,
in the presence of nimodipine, the levels of active p38
MAPK did not differ significantly from the control
upon CXCL12 exposure.
In separate experiments, we treated mixed neuronal-
glial cerebrocortical cell cultures for 12 h with 20 nM
CXCL12 in the presence or absence of 10 μM MK-801
or 10 nM nimodipine. Controls received vehicle or one
of the Ca2+ channel inhibitors without CXCL12. Follow-
ing incubation, the cells were fixed, permeabilized, and
labeled for phosphorylated p38 MAPK and neuronal
MAP-2 as described in the “Methods” section. Analysis
by immunofluorescence microscopy confirmed the loca-
tion of phosphorylated p38 MAPK in neurons. Moreover,
fluorescence intensity for phosphorylated p38 MAPK
appeared increased by exposure to CXCL12 and dimin-
ished in the presence of MK-801, but not nimodipine,
with and without CXC12, Fig. 6. Thus, the immunofluor-
escence microscopy of phosphorylated p38 MAPK sup-
ported the findings in the Western blotting experiments.
Inhibition of p38 MAPK protects cerebrocortical neurons
from CXCL12 toxicity
In analogy to the experiment with the Ca2+ channel
blockers, we incubated cerebrocortical cells for 24 h with
20 nM of CXCL12 in the presence or absence of the p38
MAPK inhibitor SB203580 (SB, 10 μM). DMSO (0.1 %)
served as vehicle control in the absence of SB203580
and BSA (0.001 %) as protein carrier control in the
absence of CXCL12. Neuronal survival was assessed by
fluorescence microscopy and cell counting as described
in the “Methods” section after the cell cultures were fixed,
permeabilized, and fluorescently labeled for neuron-
specific microtubule-associated protein-2 (MAP-2) and
nuclear DNA. Comparison of neuronal cell numbers
between the experimental conditions confirmed that
inhibition of p38 MAPK prevented CXCL12 from indu-
cing significant neurotoxicity, Fig. 7.
Fig. 5 Ca2+ channel blockers limit activity of p38 MAPK in cerebrocortical cells upon exposure to CXCL12. Rat cerebrocortical cells were incubated for
the indicated time periods with CXCL12 (20 nM) in the presence or absence of MK-801 (10 μM) or nimodipine (10 nM), prior to cell lysis on ice. 30 μg
of protein per lane were analyzed by Western blotting using the specific antibodies against the indicated molecules. A representative immunoblot is
shown for each time point. Quantification by densitometry; n = 3 to 4 per time point; *P≤ 0.05, **P≤ 0.01 by ANOVA followed by Fisher’s PLSD post
hoc test
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Discussion
In the CNS, the functions of CXCR4 and CXCL12
include beyond cell migration also the regulation of
development, axonal outgrowth and patterning, synaptic
function, and plasticity as well as decisions about cell
death and survival (reviewed in [4–6, 8, 9, 31–35]). We
confirmed recently that CXCL12 is constitutively
expressed in the murine CNS [30] and demonstrated in
vitro that about 93 % of cerebrocortical cells, virtually all
neurons and microglia, and 88 % of astrocytes expressed
CXCR4 protein [13]. Moreover, we showed in vitro that
CXCL12 triggered a transient increase of intracellular
Ca2+ levels in cerebrocortical neurons [13].
Earlier, we found that full-length CXCL12 is toxic to
terminally differentiated cerebrocortical neurons via a
pathway that depended on CXCR4 and implicated p38
MAPK [12, 13, 36]. Others linked neurotoxic CXCR4
activation to astrocytic release of glutamate that is sti-
mulated via a pathway comprising TNFα, prostaglandins,
and required microglial activation [19]. In addition,
potassium channels have recently been shown to play a
role in CXCR4-mediated induction of neuronal death
[37]. Here, we showed that blockade of NMDAR-gated
ion channels and L-type Ca2+ channels both prevent
CXCR4-mediated toxicity of CXCL12 in cerebrocortical
neurons and thus established a link between the CXCL12
induced neuronal death and cellular Ca2+ regulation.
Excessive Ca2+ influx via NMDAR occurs in neuronal
excitotoxicity [17, 38]. Therefore, our results indicated
a link between the injurious effect of CXCL12 and
excitotoxicity, a finding which was in line with the report
by Bezzi and colleagues that CXCL12 triggered astrocytic
glutamate release [19].
Since we had previously shown that CXCL12 induces
a transient increase of intracellular Ca2+ levels in neu-
rons [13] and others demonstrated that activation of
p38 MAPK in neurons is influenced by intracellular
Ca2+ levels [21], we wondered if CXCL12 significantly
increased in cerebrocortical neurons the baseline activity
of the p38 MAPK. Our experiments confirmed that
CXCL12 transiently increased activity of neuronal p38
MAPK, but not JNK, significantly above baseline. In
contrast, p38 MAPK activity was strongly reduced by
blocking neuronal NMDAR with MK-801 and kept overall
similar to control levels by blocking L-type Ca2+ channels
with nimodipine. Thus, while inhibition of L-type Ca2+
channels did not suppress p38 MAPK activity significantly
below the baseline, it still prevented a significant increase
which seems to be required for induction of neuronal
death [24].
While Ca2+-permeable NMDAR are primarily expressed
in neurons, L-type Ca2+ channels are present in neuronal
and glial cells, namely astrocytes and microglia [39–42].
However, voltage-sensitive L-type Ca2+ channels and
NMDAR-gated ion channels provide the main entry
sites for Ca2+ into neurons [42]. Similar to what has
been observed for L-type Ca2+ channels, we found that
about 93 % of cerebrocortical cells, neurons and glia,
express CXCR4 protein [13]. Considering the reported in-
volvement of astrocytes and microglia in CXCL12-induced
Fig. 6 Phosphorylated p38 MAPK localization in neurons in the presence of CXCL12 and Ca2+ channel blockers. Cerebrocortical cell
cultures were exposed to CXCL12 (20 nM), nimodipine (10 nM), or MK801 (10 μM) or combinations thereof for 12 h. Afterwards, cells
were fixed, permeabilized, and stained for MAP-2 (red), activated/phospho p38 MAPK (green) and nuclear DNA (DRAQ5; shown in blue
pseudocolor for better visualization). Images were analyzed using fluorescence microscopy as described in the “Methods” section. The
overlap of red and green signals appears yellow in the merged images. Scale bars, 20 μm
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glutamate release and toxicity, it seemed probable that
nimodipine, in contrast to MK-801, exerted its neuropro-
tective effect through interaction with all cerebrocortical
cell types. Future studies will aim at distinguishing what
the contribution of glial versus neuronal L-type Ca2+
channels is in the response to CXCL12.
In a recent study, investigating neurotoxicity triggered
by HIV-1 envelope protein gp120, we found that active
p38 MAPK primarily resided in neurons [24], which is
in line with the pronounced effect of NMDA receptor
blockade by MK-801 on the kinase’s activity in the present
study. Furthermore, Ca2+ influx via NMDAR-gated ion
channels has been shown to activate neuronal p38 MAPK
and excitotoxic death [21] and thus fits with our findings
that CXCL12-induced neuronal cell death is associated
with a transient increase in neurons of intracellular Ca2+
[13] and of p38 MAPK activity, as shown here with kinase
assays, Western blotting, and immunofluorescence.
Moreover, our confirmation that direct pharmacological
blockade of p38 MAPK can prevent CXCL12 neurotox-
icity supports the notion that limiting or diminishing the
activity of the stress kinase in neurons by inhibition of
L-type Ca2+ channels and NMDAR, respectively, is a
critical component of the neuroprotective mechanism.
Hence, our findings indicate that both types of Ca2+
channels can control CXCL12-induced neuronal death
upstream of p38 MAPK. Figure 8 summarizes our
findings in a schematic representation.
The best recognized pathological function of CXCR4 is
its role as a co-receptor during infection with HIV-1 [10].
Furthermore, we and others have shown that CXCR4 can
mediate the induction of neuronal injury and apoptosis by
HIV-1 envelope protein gp120 [12–16, 30, 43]. The neuro-
toxic process downstream of chemokine receptor engage-
ment by HIV-1 or its envelope protein gp120 also involves
excessive excitatory activation of the NMDAR (excitoto-
xicity) which in turn can be blocked by the same Ca2+
channel inhibitors that we used in the present study [17].
On the other hand, elevated levels of CXCL12 mRNA
have been reported for brain specimen from HIV ence-
phalitis (HIVE) patients as compared to uninfected con-
trols [16, 44], and we and others have shown that protein
expression of CXCL12 also appears to be elevated in the
brains of HIV patients [45, 46]. Macrophages infected with
HIV-1 have been suggested to induce astrocytosis via
CXCL12 and matrix metalloproteinases [47], and HIV-1-
infected as well as immune activated macrophages have
been reported to regulate astrocyte CXCL12 production
through IL-1β [48]. All these observations suggest the pos-
sibility that under pathological conditions, such as HIV
infection, an increase of CXCL12 concentrations beyond
physiological levels could contribute to neuronal injury.
However, recently published data suggested two seem-
ingly opposing scenarios regarding the function of the
CXCR4-CXCL12 axis during HIV infection. First, the
CXCR4-CXCL12 interaction can promote neurocogni-
tive impairment and CNS injury in association with HIV
infection in the same way described in the present study
[12, 13, 36, 46]. On the other hand, a different set of
studies proposed that the same receptor-ligand system
could ameliorate HIV-induced brain injury by suppor-
ting neuronal survival [14, 49]. The two scenarios are
not necessarily exclusive, because one possible explan-
ation is that the overall effect of the CXCR4-CXCL12
interaction depended on its exact context, such as the
composition, type, and age of the neuronal cell culture
or, in vivo, the specific brain region where the receptor-
ligand system was engaged.
Fig. 7 Pharmacological inhibition of p38 MAPK protects
cerebrocortical neurons from toxicity of CXCL12. Cerebrocortical cell
cultures were incubated with CXCL12 (20 nM) in the presence and
absence of p38 MAPK inhibitor SB203580 (SB, 10 μM) for 24 h. Analysis
of neuronal survival was performed as described in the “Methods”
section using staining for neurons (MAP-2) and nuclear DNA (H33342).
Values are mean ± SEM; n≥ 3 with duplicate or triplicate samples per
condition; **P≤ 0.01, ***P≤ 0.001 by ANOVA followed by Fisher’s PLSD
post hoc test
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Our present study revealed that the combination of
20 nM CXCL12 with 10 μM MK-801 lacked any neuro-
toxicity, whereas CXCL12 and MK-801 each killed a
significant number of neurons when applied separately
at the same concentrations. Toxicity of MK-801 towards
cerebrocortical neurons and microglia has previously
been observed but was found to be preventable in both
cell types in the presence of glutamate [50–53]. MK-801
indiscriminately blocks synaptic and extra-synaptic
NMDAR but physiological Ca2+ influx through synaptic
NMDAR triggers survival signals in neurons [54]. Thus,
the absence of neurotoxicity in cerebrocortical cells
under the condition of combined exposure to CXCL12
and MK-801 suggested that not only MK-801 blocked
CXCL12’s detrimental effect but that CXCL12 might
paradoxically in turn have protected neurons in a situ-
ation where a neuronal survival-threatening blockade of
NMDARs by MK-801 occurred. However, this hypothe-
tical explanation requires further investigation.
Conclusions
Stimulation of CXCR4 by the chemokine CXCL12 can in-
duce toxicity in cerebrocortical neurons in a concentration-
dependent fashion. CXCL12 induces an increase of
neuronal p38 MAPK activity that is counteracted by
blockade of NMDAR-gated and L-type Ca2+ channels.
Pharmacological inhibition of NMDAR-gated and L-type
Ca2+ channels as well as p38 MAPK each abrogates
neurotoxicity of CXCL12. Hence, our study indicates that
NMDAR-gated and L-type Ca2+ channels are in addition
to p38 MAPK critical components of the neurotoxic
mechanism induced by CXCL12. Moreover, our findings
suggest that both types of Ca2+ channels can control
CXCL12-induced neuronal death upstream of p38 MAPK.
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